Management of Prolonged Heavy Menstrual Bleeding in Copper IUD Users

Initial Assessment

• Heavy or prolonged bleeding is common and generally not harmful during the first 3–6 months after copper IUD insertion, and it usually diminishes with continued use (CDC). 1
• In women who have used a copper IUD for several months or longer and develop new‑onset heavy or prolonged bleeding, a clinical evaluation is required to exclude underlying pathology (CDC). 2

Diagnostic Evaluation

• When evaluation is indicated, clinicians should:
• If any underlying gynecologic problem (e.g., displaced IUD, infection, polyps/fibroids) is identified, it should be treated or the patient referred for appropriate care (CDC). 2

Medical Management

First‑Line Therapy – NSAIDs

• Prescribe a non‑steroidal anti‑inflammatory drug for short‑term use (5–7 days) during the days of bleeding (CDC). 1
• Evidence is strong: nine randomized studies showed that oral NSAIDs (e.g., indomethacin, mefenamic acid, diclofenac) produced statistically significant reductions in mean total menstrual blood loss compared with placebo or baseline (high‑quality evidence). 1
• All but one NSAID study demonstrated benefit for heavy or prolonged bleeding (moderate‑to‑high evidence). 2

Alternative Therapy – Tranexamic Acid

• Tranexamic acid can markedly reduce mean menstrual blood loss in copper IUD users with heavy bleeding (moderate evidence). 1
• Contraindicated in women with active thromboembolic disease or a history/high intrinsic risk for thrombosis, per FDA warning (CDC). 1
• Overall safety data for tranexamic acid in this setting are limited (low‑moderate evidence). 2

Agents to Avoid – Aspirin

• Aspirin should not be used for bleeding control; it showed no benefit in women with pretreatment loss > 60 mL and actually increased loss in those with baseline loss < 60 mL (CDC). 1

When Medical Management Fails

• If bleeding persists despite NSAID (or tranexamic) therapy and is unacceptable to the patient, counsel the woman on alternative contraceptive options and offer a different method if desired (CDC). 1

Counseling and Reassurance

• Reassure patients that bleeding irregularities associated with copper IUDs are generally not harmful (CDC). 1
• Providing enhanced counseling about expected bleeding patterns has been shown to reduce contraceptive discontinuation in clinical trials of other methods (moderate evidence). 7

Common Pitfalls to Avoid

• Do not assume all bleeding is benign; always consider underlying pathology, especially in established users with new‑onset symptoms (CDC). 2
• Recognize that evidence for specific NSAID or tranexamic acid dosing regimens and treatment durations is limited; recommendations are based on general efficacy data rather than precise protocols (CDC). 1